SENISCA

Senisca is a preclinical-stage biotechnology company developing oligonucleotide and small molecule therapeutics that reverse cellular senescence by restoring RNA splicing factor activity.

Its platform targets the molecular mechanisms of cellular ageing and has broad applicability across multiple age-related diseases.

Lead indications include idiopathic pulmonary fibrosis, osteoarthritis, and age-related macular degeneration.

The company also pursues a cosmeceutical programme targeting aesthetic signs of skin ageing.